Oncology Biosimilars Market Scope And Analysis

Report Code : TIPRE00002766
Category : Life Sciences

No. of Pages : 150

Buy Now

Oncology Biosimilars Market Scope, Growth, Size and Share by 2031

Buy Now

Oncology Biosimilars Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 9.46 Billion
Market Size by 2031	US$ 24.71 Billion
Global CAGR (2023 - 2031)	12.8%
Historical Data	2021-2023
Forecast period	2023-2031
Segments Covered	By Drug Class Monoclonal Antibodies Granulocyte Colony-Stimulating Factor Erythropoiesis-Stimulating Agents By Cancer Type Colorectal Cancer Cervical Cancer Breast Cancer Supportive Care Lymphoma By and Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	CELLTRION Inc Teva Pharmaceutical Industries Ltd Pfizer Inc Sandoz Group AG Biocon Amgen Inc Samsung Bioepis Coherus BioSciences BIOCAD

Industry Developments and Future Opportunities:

The oncology biosimilars market forecast can help stakeholders in this marketplace plan their growth strategies. As per the company press release, below are a few key developments and initiatives taken by key players operating in the oncology biosimilars market:

In November 2022, Organon launched a biosimilar of Avastin, AYBINTIO, in Canada. The treatment is available for patients in Canada who are affected by certain aggressive forms of cancer, including metastatic colorectal cancer (mCRC); metastatic lung cancer; platinum-sensitive and resistant recurrent epithelial ovarian, including fallopian tube and primary peritoneal cancer; and glioblastoma. This launch aims to expand the company's biosimilar portfolio.
In May 2022, Biocon Biologics and Viatris launched Abemy, a biosimilar to Roche’s Avastin (Bevacizumab). Biocon Biologics Ltd., a subsidiary of Biocon Ltd., and Vietris’ Inc. announced the availability of this oncology biosimilar in Canada. bevy, co-developed by Biocon Biologics and Vietri’s, has been approved by Health Canada for four types of cancers.
In April 2020, Pfizer received approval from the European Commission (EC) for RUXIENCE, which is a monoclonal antibody (mob) and biosimilar to Mather (rituximab). This approval was for treating certain cancers, such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and autoimmune conditions.
In January 2020, Chorus Biosciences entered into a license agreement with Innocents Biologics Co., Ltd. for the development and commercialization of bevacizumab (Avastin) biosimilar of any dosage form and presentation in the US and Canada.

Competitive Landscape and Key Companies:

CELLTRION, Inc.; Teva Pharmaceutical Industries Ltd; Pfizer Inc; Sandoz Group AG; Biocon; Amgen Inc; Samsung Bioepis; Coherus BioSciences; BIOCAD; and Lilly are among the top players profiled in the oncology biosimilars market report. These companies focus on presenting new hi-tech products, technological advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.